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Abstract
Objective: Since tumor radiation response is oxygen-dependent, radiosensitivity can be enhanced by increasing tumor
oxygenation. Theoretically, inhibiting cellular oxygen consumption is the most efficient way to increase oxygen levels. The
cationic, rhodacyanine dye-analog MKT-077 inhibits mitochondrial respiration and could be an effective metabolic inhibitor.
However, the relationship between cellular MKT-077 uptake and metabolic inhibition is unknown. We hypothesized that rat
and human mammary carcinoma cells would take up MKT-077, causing a decrease in oxygen metabolism related to drug
uptake.
Methods: R3230Ac rat breast adenocarcinoma cells were exposed to MKT-077. Cellular MKT-077 concentration was
quantified using spectroscopy, and oxygen consumption was measured using polarographic electrodes. MKT-077 uptake
kinetics were modeled by accounting for uptake due to both the concentration and potential gradients across the plasma
and mitochondrial membranes. These kinetic parameters were used to model the relationship between MKT-077 uptake
and metabolic inhibition. MKT-077-induced changes in oxygen consumption were also characterized in MDA-MB231 human
breast carcinoma cells.
Results: Cells took up MKT-077 with a time constant of ,1 hr, and modeling showed that over 90% of intracellular MKT-077
was bound or sequestered, likely by the mitochondria. The uptake resulted in a rapid decrease in oxygen consumption, with
a time constant of ,30 minutes. Surprisingly the change in oxygen consumption was proportional to uptake rate, not
cellular concentration. MKT-077 proved a potent metabolic inhibitor, with dose-dependent decreases of 45–73% (p=0.003).
Conclusions: MKT-077 caused an uptake rate-dependent decrease in cellular metabolism, suggesting potential efficacy for
increasing tumor oxygen levels and radiosensitivity in vivo.
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Introduction
Solid tumors are significantly hypoxic [1] because of an
imbalance in oxygen supply and demand. Hypoxia negatively
impacts the efficacy of various tumor treatments, especially
radiation therapy [2,3]. This well-known effect is directly related
to the mechanism of radiation-induced cell death. DNA damage
from ionizing radiation is made permanent when molecular
oxygen, present at the time of radiation, binds to DNA strand
breaks [4], ultimately causing cellular death. Diminished oxygen
levels yield cells that are more likely to repair the radiation-
induced defects using their DNA repair machinery, escaping this
death pathway. Where hypoxia exists, larger radiation doses are
required to obtain similar outcomes as achieved under normoxic
conditions [1,4,5,6]. Therefore, there has been considerable effort
to increase tumor oxygen levels as a means of increasing
radiosensitivity [7].
Tumor hypoxia can be reduced by either increasing oxygen
supply to the tumor or decreasing the tumor’s demand for oxygen.
Theoretical modeling has demonstrated that reducing oxygen
consumption (demand) is the most effective method [8,9,10].
Small decreases in consumption (#30%) translate into large
increases in local oxygen levels. This effect has been demonstrated
in conjunction with radiation in a study investigating glucocorti-
coids as metabolic inhibitors in intramuscular murine tumors [11].
In this study, the delocalized lipophilic cation MKT-077 was
investigated as an inhibitor of cellular oxygen consumption, and
the kinetic relationship between drug uptake and metabolic
inhibition was characterized. This compound had been tested
preclinically as a chemotherapeutic agent, where it preferentially
accumulated in carcinomas and was extremely cytotoxic in in vitro
and in vivo models [12,13,14,15,16,17,18]. Since the drug
accumulated in the mitochondria, its cytotoxicity was originally
primarily attributed to mitochondrial damage and nonspecific
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[15,16,18]. This inhibition of electron transport resulted in a
decrease in mitochondrial oxygen consumption. MKT-077 was
advanced to Phase I clinical trials, but its progression was halted,
due to limited antitumor effects and mild nephrotoxicity [19,20].
Since MKT-077 has been shown to inhibit respiration in isolated
mitochondria [16] and has been advanced to clinical trials, it is
possible that this drug could be a useful radiosensitizer by raising
local tumor oxygen levels.
Although MKT-077 accumulates in mitochondria and inhibits
isolated mitochondrial oxygen consumption [15,16], the relation-
ship between cellular drug uptake and the extent of cellular
metabolic inhibition is unknown. Since the plasma membrane and
other cellular components can influence drug uptake, it is
important to determine MKT-077 uptake and uptake kinetics in
whole cells. Our hypothesis was that MKT-077 would be taken up
by breast adenocarcinoma cells in a dose- and time-dependent
manner and that the inhibition of cellular oxygen consumption
would be related to the drug uptake. The results of these studies
will guide future in vivo characterization of MKT-077 as a possible
tumor metabolic inhibitor. Since inhibition of oxygen consump-
tion will increase tumor oxygen levels, MKT-077 could have the
potential to increase hypoxic tumor radiosensitivity.
Methods
MKT-077
MKT-077 (1-Ethyl-2-{[3-ethyl-5-(3-methyl-benzothiazolin-2-
yliden)]-4-oxothiazoli-din-2-ylidenemethyl}pyridium chloride)
was a generous gift of Dr. Keizo Koya (Synta Pharmaceuticals
Corp., Lexington, MA). MKT-077 was dissolved in saline (1 mg/
ml), and MKT-077 calibration solutions were prepared by serial
dilution. Solution absorbance was measured at 495 nm [15], using
a BioRad SmartSpec 3000 spectrophotometer (Hercules, CA).
The resultant standard curve was used to determine the MKT-077
concentrations in subsequent experiments.
Growth of R3230Ac and MDA-MB231 Cells
The R3230Ac rat breast adenocarcinoma cells used in this study
were a gift from Dr. Mark Dewhirst (Duke University Medical
School, Durham, NC). The R3230Ac cell line spontaneously arose
from a rapidly growing lactating rat mammary tumor (R3230AB)
in the Fischer 344 rat [21]. Cells were grown under standard
incubator conditions in Dulbecco’s Modified Eagle Medium (D-
MEM), with high glucose, L-glutamine, and sodium pyruvate,
supplemented with penicillin-streptomycin and 10% fetal bovine
serum. After growth to ,80–90% confluency, cells were harvested
and resuspended to 1610
6 cells/ml in phenol red-free D-MEM
with identical supplementation. Since MKT-077 is orange, phenol
red-free media was used to limit background spectroscopic
interference.
A subset of experiments was also performed on MDA-MB231
human breast carcinoma cells, which were purchased from the
American Type Culture Collection (ATCC, Manassas, VA). The
MDA-MB231 breast cancer cell line was generated from a pleural
effusion in a 51 year-old patient at M. D. Anderson Cancer Center
in 1973 [22]. Cells were grown and maintained in Leibovitz’s L-15
media (LL-15) plus antibiotics and 10% fetal bovine serum.
In Vitro MKT-077 Uptake
A 15 ml suspension of cells was placed in a water-jacketed
chamber equilibrated to 37uC and was gently mixed with a small
magnetic stir bar. After obtaining a negative control sample,
MKT-077 was added to the system to bring the concentration to
2, 4, or 6 mg/ml. 1.5 ml samples were taken immediately and
every 30 minutes thereafter over two hours. Samples were
centrifuged, washed with PBS, and lysed with 200 ml ethanol.
Samples were then re-centrifuged, and the lysate was analyzed
spectrophotometrically at 495 nm. In addition to the 1.5 ml
sample, a 100 ml aliquot was taken from the chamber to determine
cell viability using the trypan blue exclusion technique [23]. The
chamber and samples were continuously protected from light,
since MKT-077 is photosensitive [24].
Model of Cellular MKT-077 Uptake
As detailed in the Appendix S1, cellular uptake of MKT-077
was modeled by assuming that drug uptake is driven by a
combination of the concentration gradient and the electrical
potential gradient across the plasma membrane. By using the
constant field assumption of Goldman [25] to describe the
transmembrane drug flux, the intracellular drug concentration
can be described at any time t by:
CC~100,000(1zb)VC CM0ec 1{e
kct
(1zb)1 {ec ðÞ
  
ðEq 1Þ
where CC=total intracellular drug concentration (ng MKT-077/
10
5 cells), b=equilibrium constant (dimensionless) relating the
mitochondrial MKT-077 concentration to the cytoplasmic MKT-
077 concentration, VC=cellular volume (ml/cell), CM0=initial
MKT-077 concentration in the medium (ng MKT-077/ml),
k=mass transfer coefficient across cell membrane (sec
21), and
c=dimensionless parameter related to the plasma membrane
potential, DYpmem (see Appendix S1).
As t approaches infinity, CC reaches a final steady-state value,
CC,‘ (ng MKT-077/10
5 cells), and Equation 1 reduces to:
CC,?~100,000(1zb)VC ecCM0~wCM0 ðEq 2Þ
where
w~100,000(1zb)VC ec
Substituting Equation 2 into Equation 1 yields:
CC~CC,? 1{ekt ðÞ ð Eq 3Þ
where
k~
kc
(1zb)1 {ec ðÞ
ðEq 4Þ
The initial uptake rate [ng MKT-077/(10
5 cells min)] is given by:
dCC
dt
       
t~0
~{kCC,?~{100,000
kc
1{ec
  
VC ec CM0 ðEq 5Þ
To determine the value of VC, images of MKT-077-treated
(4 mg/ml) and untreated cells were taken at all time points on an
inverted phase-contrast microscope fitted with a digital camera (Q-
Color 3, Olympus America, Center Valley, PA) using QCapture
Pro software (QImaging Corp., Surrey, BC, Canada). Cell
diameters (d) were measured from the digital images using ImageJ
software (NIH, Bethesda, MD). Average cell volume was
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3/6) using a minimum of 150 cells per
time point.
The value of DYpmem was determined using a modification of
t h em e t h o do fE m r ie ta l .[ 2 6 ] .B r i e f l y ,R 3 2 3 0 A cc e l l sw e r e
harvested and either left in D-MEM medium or fixed in cold
10% buffered formalin for 30 minutes. Then 4610
5 cells/ml
suspensions of fixed and unfixed cells were exposed to different
concentrations of the anionic dye DiBAC4(3) for 30 minutes at
37uC. Aliquots of 4610
4 cells at each drug exposure were placed
in a 96-well plate. Fluorescent intensity readings were measured
spectrophotometrically with excitation and emission wave-
lengths of 493 and 519 nm, respectively (Spectra Max Gemini
EM, Molecular Devices, Sunnyvale, CA). The intensities of the
unfixed cells yielded the intracellular concentrations as a
function of DiBAC4(3) concentration in the media. Using the
intensity curve from the unfixed cells as a calibration, the
intensity of the fixed cells was used to determine the
extracellular concentration on a cellular basis. The membrane
potential was calculated by substituting the ratio of the two
concentrations into the Nernst equation. The value of DYpmem
was then used to calculate c for use in the model equations (see
Appendix S1).
Equation 1 was fitted to the uptake data by optimizing the
parameters b and k using nonlinear least-squares regression
(GraphPad Prism, GraphPad Software, Inc., La Jolla, CA). The
goodness of fit was determined by evaluation of the coefficient of
determination (r
2) and the root-mean-square (RMS) error. The
validity and uniqueness of b and k were assessed by evaluating the
95% confidence intervals, which indicate how tightly the model
has determined these values.
Estimation of Mitochondrial Membrane Potential
If it is assumed that the vast majority of ‘‘bound’’ MKT-077 is
found within the mitochondria, then the relationship between the
mitochondrial transmembrane potential, DYmit, and the cytoplas-
mic and mitochondrial concentrations is given by the Nernst
equation and can be calculated as follows at 37uC:
DYmit~{0:03744ln
b
Vmit
  
ðEq 6Þ
where Vmit=relative mitochondrial volume (ml mitochondria/ml
cell). Vmit was assumed to be 0.10, which is the mitochondrial
volume fraction of HeLa cervical cancer cells [27].
In Vitro Measurement of Oxygen Tension in a Closed
System
Oxygen tension (pO2) was measured using a Clark-type
polarographic oxygen electrode (inO2, Innovative Instruments,
Inc., Tampa, FL). Saline was equilibrated to 37uC in a water-
jacketed chamber, and a calibration line was obtained by
measuring the electrode current in saline bubbled with gases of
known oxygen concentrations (21%, 5%, and 0% O2). The
calibration line was used to convert the measured current into
pO2. After calibration, 5.25 ml of R3230Ac or MDA-MB231 cell
suspension (5.25610
6 cells) was placed into the chamber. The
electrode was inserted into the suspension, which was gently
mixed with a small magnetic stir bar, and the chamber was
sealed. The oxygen current was recorded at 20 Hz (DaqPAD and
LabVIEW, National Instruments, Austin, TX). After a baseline
recording (20 minutes), the appropriate volume of MKT-077
stock solution was injected into the system to achieve a
concentration of 2, 4, or 6 mg/ml (30 ml maximum). Saline was
used for controls. The pO2 was then recorded for two hours or
until a threshold of 20 mm Hg was reached. This threshold value
was chosen, since the consumptive behavior of cells changed
below 20 mm Hg, regardless of treatment condition. At the end
of the experiment, the cellular MKT-077 concentration was
determined spectrophotometrically. Oxygen currents were pro-
cessed by taking a two-second average every 30 seconds
(DIAdem, National Instruments, Austin, TX). Data was analyzed
after the currents were converted to pO2 using the electrode
calibration. Exposure of electrodes to concentrations of MKT-
077 up to 6 mg/ml had no effect on the electrode current (data
not shown).
Modeling the Relationship between MKT-077 Uptake and
Oxygen Consumption Change
To quantify the effect of MKT-077 on oxygen consumption, we
tested numerous models relating the change in oxygen consump-
tion to MKT-077 uptake. It is reasonable to assume that the
change in consumption would be related to the amount of MKT-
077 sequestered in the mitochondria or the rate at which MKT-
077 was taken up by the mitochondria. Since the amount of
sequestered drug is proportional to the total cellular MKT-077
concentration, CC, the change in consumption can also be related
to CC, which is a measured variable (see Appendix S1). To
determine the nature of the relationship between consumption
change and cellular uptake of MKT-077, we tested the following
three relationships:
dq
dCC
~{a0 ð‘‘constant00 model;Eq 7Þ
dq
dCC
~{a1CC ð‘‘uptake00 model;Eq 8Þ
dq
dCC
~{a2
dCC
dt
  
ð‘‘rate00 model;Eq 9Þ
where dq/dCC=the change in cellular oxygen consumption for a
given change in cellular MKT-077 concentration {ml O2/[(ng
MKT-077) min]}, a0=proportionality constant {ml O2/[(ng
MKT-077) min]}, a1=proportionality constant {[ml O2 (10
5
cells)]/[(ng MKT-077)
2 min]}, and a2=proportionality constant
{[ml O2 (10
5 cells)]/[(ng MKT-077)
2]}. The models represented
by Equations 7, 8, and 9 are designated the ‘‘constant’’, ‘‘uptake’’,
and ‘‘rate’’ models, respectively.
As described in the Appendix S1, Equations 7–9 can be
integrated and simplified to yield the oxygen consumption as a
function of time after MKT-077 addition at time t=0:
q(t)~q1, t ƒtƒ0 ðEq 10Þ
q(t)~q1{a0 CC,? 1{ekt ðÞ , t§0 ð‘‘constant00 model;Eq 11Þ
or q(t)~q1{
a1 C2
C,?
2
 !
1{ekt ðÞ
2, t§0ð‘‘uptake00 model;Eq 12Þ
’’
’’
’’
’’
’’
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ka 2C2
C,?
2
 !
1{e2kt   
, t§0 ð‘‘rate00 model;Eq 13Þ
where q1=basal O2 consumption rate [ml O2/(10
5 cells min)] and
t
*=time at which the recording was started.
As detailed in the Appendix S1, these relationships were used to
obtain equations describing pO2 as a function of time and three
unknown parameters (P
*,q 1, and a0, a1,o ra2):
P(t)~P {
N
kO2
  
q1 t{t  ðÞ , t ƒtv0 ðEq 14Þ
P(t)~P {
N
kO2
  
q1 t{t  ðÞ z
Na0 CC,?
kO2
  
tz
1
k
1{ekt ðÞ
  
, t§0
ð‘‘constant00;Eq15Þ
P(t)~P {
N
kO2
  
q1 t{t  ðÞ z
N
kO2
  
a1 C2
C,?
2
 !
tz
1{ekt ðÞ
2k
3{ekt ðÞ
  
, t§0
ð‘‘uptake00;Eq16Þ
P(t)~P {
N
kO2
  
q1 t{t  ðÞ {
N
kO2
  
ka 2C2
C,?
2
"#
tz
1{e2kt
2k
  
, t§0
ð‘‘rate00;E q1 7 Þ
where P=pO2 (mm Hg), P
*=initial pO2 at time t
* (mm Hg),
N=cellular concentration (1610
6 cells/ml suspension), and
kO2=oxygen solubility (Henry’s Law constant) of the suspension
(ml O2/ml suspension/mm Hg).
In all cases, the value of kO2 was set to 3.0610
25 ml O2/(ml
suspension mm Hg), which is the oxygen solubility in a dilute
protein solution at 37uC [28]. The values of k and CC,‘ were
determined from the fits of the uptake data. Using these constants,
the experimental pO2 data were fitted to Equations 14–17 by
optimizing values of P*, q1, and a (a0, a1,o ra2) using nonlinear
least-squares regression (GraphPad Prism, GraphPad Software,
Inc., La Jolla, CA).
The goodness of fit was determined by evaluation of the r
2 and
RMS error values. The validity and uniqueness of the parameter
values were assessed by evaluating the 95% confidence intervals.
All of the data were fitted to these models, except for the saline
control data, which were fitted to a straight line, since the rate of
oxygen consumption remained constant.
Statistics
All mean values are reported as means 6 SD. Since all
parameters for the R3230Ac cells passed normality tests,
parametric statistical tests were used for all comparisons. The
uptake curves of the three groups were compared using two-way
analysis of variance (two-way ANOVA). Model parameter values
were compared among the dose groups using one-way ANOVA.
Viability data as a function of time within each dose group were
compared using one-way ANOVA. Significant differences
(p,0.05) were further analyzed using Bonferroni’s multiple
comparison test to compare values between any two groups.
Correlations among parameter values and MKT-077 concentra-
tion were determined using linear regression analysis. Regressions
were considered significant if p,0.05.
Since the group sizes were smaller for the MDA-MB231 cells,
model parameter values were compared among the dose groups
using the nonparametric Kruskal–Wallis one-way ANOVA by
ranks test.
Since all of the oxygen consumption models contained three
unknown parameters, comparisons of the model fits were made
using a repeated measures one-way ANOVA test of the RMS
errors and r
2 values. Significant differences (p,0.05) were further
analyzed using Bonferroni’s multiple comparison test to compare
values between any two groups. Differences were considered
significant if p,0.05.
Results
Effect of MKT-077 Exposure on Cell Viability
The average viability remained well above 90% for all
experiments. For the 2 and 4 mg/ml treatment groups, there was
no significant effect of MKT-077 exposure time on cell viability
(one-way ANOVA, p=0.064 and p=0.234, respectively). Thus,
there was no significant change in the fraction of viable cells at the
end of the observation period (90–120 minutes) compared to the
starting viable fraction: 94.364.1% vs. 97.162.9% (n=11) for the
2 mg/ml dose and 97.161.9% vs. 98.161.8% (n=10) for the 4 mg/
ml dose. For the 6 mg/ml treatment group, there was a small, but
significant, decrease in cell viability over time (one-way ANOVA,
p=0.0003). At the start of the experiment, the average viability was
98.461.7% (n=8), while after 120 minutes it was significantly
lower at 93.963.7%(Bonferroni’s test, p,0.01).In this group, there
were no significant differences between the viability at 30 and
60 minutes compared to the starting value (p.0.05).
Model of In Vitro MKT-077 Uptake
Since cell volume did not change as a function of MKT-077
exposure, VC was set to the average cell volume of
17476519 mm
3/cell (mean6SD, n=718) or 1.747610
29 ml/
cell. Plasma membrane potential was measured in five separate
experiments, with DYpmem=226.162.8 mV. Using this value
and Equation A4 in the Appendix S1, c was calculated as 0.9772.
Figure 1A shows an example of the fit of the model to
experimental data obtained when R3230Ac cells were treated with
4 mg/ml MKT-077. In this example, b was 16.58 and k was
0.427 min
21. The 95% confidence intervals were 11.65–21.51 for
b and 0.305–0.549 min
21 for k. The RMS error was 0.929 ng/
10
5 cells, and r
2 was 0.994. Qualitatively, there was a relatively
rapid rise in the cellular concentration of MKT-077 over the first
30 minutes after exposure. Most of this increase is attributable to
the accumulation of drug in the mitochondria or binding to other
receptors (long dashed line). Unbound drug in the cytoplasm
(dotted line) is extremely low.
Table 1 shows that this model fitted all of the data well. Values
of r
2 ranged from 0.896–1.000, indicating that the model
accounted for most of the variability in the data. The average
RMS error was less than 1.3 ng/10
5 cells. The 95% confidence
intervals also affirmed the goodness of the model fit.
Effect of Extracellular Drug Concentration on MKT-077
Uptake
The mean uptake values for each time point are shown in
Figure 1B, along with the fit of the model to these values.
’’;
’’
’’
’’
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manner (p,0.0001, 2-way ANOVA). Treatment of cells with
2 mg/ml MKT-077 (n=11) resulted in the lowest uptake at the
end of the two-hour incubation period (10.461.9 ng/10
5 cells).
Cells treated with 4 (n=10) and 6 mg/ml MKT-077 (n=7)
exhibited higher 2-hour drug levels of 28.7611.1 and
49.2610.9 ng/10
5 cells, respectively.
Uptake analysis using the kinetic model revealed no significant
difference between the b values in cells treated with 2, 4, or 6 mg/
ml MKT-077 (p=0.262, Table 1). These b values translated into
DYmit values of 2133.3 to 2139.6 mV. Similarly, there was no
significant difference in the fitted k values (Table 1), although the
value for the 6 mg/ml group tended to be slightly higher.
One-way ANOVA analysis determined that there was a
significant difference in the initial uptake rates and the steady
state MKT-077 concentrations (p,0.001, Table 1, Figures 1C, D).
The initial uptake rates for cells treated with different concentra-
tions of MKT-077 were significantly different from each other
(Figure 1C, p,0.05). Equation 5 (line in Figure 1C) predicts the
initial uptake rate for the 2 and 4 mg/ml doses well, but tends to
underestimate the value for the 6 mg/ml dose. Cells treated with
4 mg/ml and 6 mg/ml of MKT-077 each had a higher steady state
uptake compared to cells treated with 2 mg/ml (Figure 1D,
p,0.001). The line in Figure 1D is the model prediction, as given
by Equation 2. The slope, w, was calculated using the parameters
and has a value of 0.00845 ml/10
5 cells.
Comparison of Models of In Vitro pO2 and Oxygen
Consumption
To determine the drug’s impact on oxygen consumption, 6–7
experiments were performed at each MKT-077 drug level (0, 2, 4,
and 6 mg/ml). Examples of individual experiments at the 0, 2, and
6 mg/ml doses are shown in Figure 2A. The points are the
recorded pO2 values. From 220 to zero minutes (baseline), a
linear decrease in pO2 was evident in all cases, indicating an
unchanging oxygen consumption rate. The slope of the line
remained unchanged after addition of saline (0 mg/ml). After 2 or
6 mg/ml MKT-077 was added (t=0), the curve became nonlinear,
indicating a decrease in oxygen consumption (Figure 2A). As the
MKT-077 dose increased, the curve became progressively flatter,
i.e., oxygen consumption decreased further.
The pO2 data from the cells treated with saline were adequately
fitted by a straight line (Figure 2A). The pO2 data from all 20
MKT-077 dosing experiments were fitted to the three different
Figure 1. Effect of extracellular MKT-077 concentration on cellular uptake. A) Data from a typical uptake experiment. R3230Ac cells were
treated with 4 mg/ml MKT-077 at time 0. Solid line represents total cellular MKT-077 uptake, dashed line represents intracellularly bound or organelle-
sequestered drug, and dotted line indicates free drug in the cytoplasm as determined by the model. B) MKT-077 uptake by R3230Ac cells as a
function of drug concentration and time. Values are the mean 6 SEM. p,0.0001 using a two-way ANOVA. Curves are fits of the mean values to
Equation 1. 2 mg/ml: b=11.1, k=0.458 min
21 (n=11); 4 mg/ml: b=18.0, k=0.502 min
21 (n=10); 6 mg/ml: b=18.0, k=0.632 min
21 (n=7). C) Initial
drug uptake rate as a function of treatment concentration. Line is calculated from Equation 5 with a slope of 1.44610
24 ml/(10
5 cells min). D) Steady-
state MKT-077 uptake as a function of treatment concentration. Line is calculated from Equation 2 with a slope of 0.00845 ml/10
5 cells. In panels C
and D, the points are staggered along the abscissa for clarity, and the horizontal bars represent the mean values. One-way ANOVA with Bonferroni’s
Multiple Comparison Tests: * p,0.001 vs. 2 mg/ml value,
# p,0.001 vs. 4 mg/ml value,ˆp,0.05 vs. 2 mg/ml value.
doi:10.1371/journal.pone.0037471.g001
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Since there was no significant dose effect on the uptake
parameters, the overall mean values of b and k (Table 1) were
used to calculate k and Equation 2 was used to calculate CC,‘.
Therefore, k was set to 20.017 min
21, and CC,‘ was set equal to
16.9, 33.8, and 50.7 ng MKT-077/10
5 cells for the 2, 4, and
6 mg/ml doses, respectively.
Fits of a representative data set to the three models and the
predicted changes in oxygen consumption after addition of 6 mg/
ml MKT-077 at time 0 are presented in Figure 3. In this example,
the simplest model (‘‘constant’’) fitted the data fairly well, but it
overestimated the data from 0 to 15 minutes and underestimated
it from 60–80 minutes (Figure 3A). The consumption was still
decreasing after 120 minutes and seemed to be heading for an
unrealistic negative value (Figure 3B). The ‘‘uptake’’ model yielded
the worst fit and clearly underestimated the initial consumption
rate, q1, as evidenced by the shallow slope of the line between 220
and 0 minutes (Figure 3A and inset). The consumption rate had
reached zero after 120 minutes and then became negative
(Figure 3B). The ‘‘rate’’ model yielded the best fit and described
the pO2 data reasonably well (Figure 3A). The consumption had
almost reached a positive steady state value by 120 minutes
(Figure 3B).
The qualitative results evident in Figure 3 were consistent with
the quantitative analysis of all 20 fits to the three models. The
goodness-of-fit statistics for these fits are summarized in Table 2. A
repeated measures one-way ANOVA test of the RMS errors and
r
2 values revealed that there was a significant difference in both
parameters among the three models (p,0.0001, n=20). Subse-
quent testing using Bonferroni’s multiple comparison test revealed
that the goodness of fit parameters from the ‘‘uptake’’ model were
significantly worse than the parameters obtained from either the
‘‘constant’’ or the ‘‘rate’’ model (p,0.01). The ‘‘uptake’’ model
also significantly underestimated the pre-injection consumption
rate, which could be calculated from the slope of the points
between 220 and 0 minutes (Table 2). Although there was no
statistical difference in the goodness of fit parameters between the
‘‘constant’’ model and the ‘‘rate’’ model based on the Bonferroni’s
test, the simple constant model resulted in unrealistic negative
values for q in 12 of the 20 cases (Table 2). In addition, a paired t-
test of the RMS errors and the r
2 values from just the ‘‘constant’’
and ‘‘rate’’ models showed that these parameters were significantly
better for the ‘‘rate’’ model (p,0.02). Based on these consider-
ations, the ‘‘rate’’ model was chosen as the best model and was
investigated further.
Fits of In Vitro pO2 Data to ‘‘Rate’’ Model
Table 3 summarizes the results from the fits of all of the pO2
data to the ‘‘rate’’ oxygen consumption model as defined by
Equations 14 and 17. Examples of the fit of this model to pO2 data
are shown in Figure 2A, and the calculated changes in
consumption are shown in Figure 2B. As noted earlier, the control
data were fitted to a straight line, and the only parameters
obtained were the initial pO2,P
*, and the basal consumption rate,
q1, which remained constant throughout the experiment. For the
MKT-077-treated cells, the r
2 values show that the model fitted
the data well. The r
2 value for the 2 mg/ml group was slightly
higher than the value for the 6 mg/ml group (p,0.05), but all
mean r
2 values were greater than 0.99. There was no difference in
the RMS errors, and all values were near 2 mm Hg. The mean
95% confidence intervals were small, demonstrating that the fitted
parameters were unique.
Among the three fitted parameters, the only significant
difference was in the proportionality constant, a2 (ANOVA,
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37471p=0.001). The a2 value for the 2 mg/ml group was significantly
higher than that of either of the other two groups (Bonferroni’s
test, p,0.001). There was no difference in the starting pO2 value,
P*, among the groups (ANOVA, p=0.682). As expected, there
was also no difference in the baseline oxygen consumption rate, q1,
among the groups (ANOVA, p=0.061), although the mean in the
4 mg/ml dose group tended to be slightly higher.
Proportionality Constant, a2
Since a2 was significantly different for the 2, 4, and 6 mg/ml
dose groups, the relationship between a2 and the concentration of
MKT-077 in the media, CM0, was investigated further. It was
found that a2 was approximately proportional to CM0
21.5. Since,
according to Equation 2, CM0 is directly proportional to CC,‘, a2
is also proportional to CC,‘
21.5 or any combination of CM0 and
CC,‘ to the 21.5 power. Therefore, we defined a2 as:
a2~
ar
CC,?
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p ðEq 18Þ
where ar=proportionality constant {[ml O2 (10
5 cells)
0.5]/(ng
MKT-077)
0.5}. Equation 18 can be used to calculate the new
parameter ar for each fit. The average of this parameter for each
experimental group is presented in Table 3. There was no
significant difference in the new proportionality constant, ar,
among the experimental groups (ANOVA, p=0.384). Therefore,
Figure 2. Examples of the inhibition of oxygen consumption by MKT-077 and resultant model fits. A) Change in pO2 measured in
R3230Ac cell suspension before and after addition of different concentrations of MKT-077 (0, 2, or 6 mg/ml) to air-saturated medium at t=0 minutes.
Points are measured pO2 data. Curves are fits of data to the ‘‘rate’’ model (Equations 14 and 17). B) Changes in oxygen consumption, q-q1, predicted
by the ‘‘rate’’ model (Equations 10 and 13).
doi:10.1371/journal.pone.0037471.g002
Figure 3. Fits of a typical pO2 data set to the three oxygen consumption models. A) Change in pO2 measured in R3230Ac cell suspension
before and after addition of 6 mg/ml MKT-077 to air-saturated medium at t=0 minutes. Points are measured pO2 data. Curves are fits of data to the
following models: dq/dCC=2a0 (‘‘constant’’, dotted line); dq/dCC=2a1CC (‘‘uptake’’, dashed line); dq/dCb=2a2 (dCC/dt) (‘‘rate’’, solid line) [see
Equations 14–17]. The inset shows the same data from 220 to 15 minutes. B) Corresponding changes in oxygen consumption, q, predicted by the
three models (Equations 10–13).
doi:10.1371/journal.pone.0037471.g003
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37471unlike a2, ar is indeed a true proportionality constant that does not
change with drug concentration.
Substituting Equation 18 into Equation 9 yields:
dq
dCC
~{
ar
CC,?
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p
dCC
dt
  
~{
ar ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p
d
dt
CC
CC,?
     
ðEq 19Þ
Thus, the relative uptake rate [d(CC/CC,‘)/dt] is an important
parameter in determining the magnitude of the consumption
change caused by MKT-077 uptake.
The new constant ar can also be substituted into the expressions
describing the pO2 change and the consumption change after
addition of MKT-077 by inserting Equation 18 into Equations 17
and 13, respectively:
P(t)~P {
N
kO2
  
q1 t{t  ðÞ {
N
kO2
  
ka rCC,?
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p
  
tz
1{e2kt
2k
  
, t§0
ðEq 20Þ
q(t)~q1z
ka r CC,?
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p
  
1{e2kt   
, t§0 ðEq 21Þ
Effect of Drug Concentration on MKT-077-Induced
Metabolic Inhibition
Equations 20 and 21 can be used to graphically demonstrate the
impact of MKT-077 on chamber pO2 and cellular oxygen
consumption rate by using the mean parameter values in Table 3
(Figure 4). Increasing doses of MKT-077 caused an increased
flattening of the pO2 curve (Figure 4A), which was the result of a
dose-dependent increase in the MKT-077-induced decrease in
oxygen consumption rate (Figure 4B).
The quantitative impact of MKT-077 on oxygen consumption
is best described by looking at the steady-state values of oxygen
consumption. The final steady-state consumption after addition of
MKT-077, q2, can be calculated from Equation 21 by letting t
approach ‘:
q2~q1z
ka r CC,?
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p
  
ðEq 22Þ
Values of q2 were computed from Equation 22 for each
experiment, and the group means appear in Table 3. There was a
significant difference in q2 among the groups (ANOVA,
p=0.017). The q2 value was significantly lower in the group
treated with 6 mg/ml compared to the 2 mg/ml treatment group
(Table 3).
To normalize for variability in the basal consumption rates, the
percent decrease in consumption, %Dq, was calculated as:
%Dq~100
q1{q2
q1
  
~{
100
q1
  
ka r CC,?
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p
  
ðEq 23Þ
For cells treated with 2, 4, or 6 mg/ml MKT-077, the average
decreases in oxygen consumption rate were 45.5612.6% (n=7),
61.7610.2% (n=7), and 73.3613.8% (n=6), respectively
(Figure 5A). The percent decrease in consumption was dependent
on dose (ANOVA, p=0.003, Figure 5A), and the percent decrease
in consumption in the cells treated with 6 mg/ml was significantly
greater than in the cells exposed to 2 mg/ml (p,0.001).
By substituting Equation 2 into Equation 23, %Dq can be
expressed as a function of the MKT-077 concentration in the
external media, CM0:
%Dq~{100
ar kw
2q1
   ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p
ðEq 24Þ
This predicted relationship between the relative consumption
change and CM0 is shown by the solid curve in Figure 5A.
It is also informative to view the impact of final cellular drug
uptake on the total oxygen consumption decrease. For cells treated
with 2, 4, or 6 mg/ml MKT-077, the mean intracellular drug
concentrations at the end of these experiments were 11.966.5,
27.3610.1, and 43.568.4 ng/10
5 cells, respectively (p,0.0001,
ANOVA). There was a significant correlation between the uptake
of MKT-077 and percent decrease in consumption (p=0.004,
Figure 5B).
Using Equations 2 and 23, the total decrease in consumption
can be expressed in terms of final steady-state concentration, CC,‘:
%Dq~{100
ar k
2q1
   ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
wCC,?
p
ðEq 25Þ
If we assume that the final drug uptake was equal to the final
steady-state concentration, CC,‘, the relationship in Figure 5B
Table 2. Comparison of the fits of all 20 data sets to the three different models of oxygen consumption change.
Model Model Function r
2 RMS error (mm Hg)
Fitted parameter q1
[ml O2/(10
5 cells min)]
Number of fits
with q,0
‘‘Constant’’ dq
dCC
~{a0
0.994060.0034
b 2.27160.522
a 4.1460.88610
26 5
‘‘Uptake’’ dq
dCC
~{a1 CC
0.991360.0062
c 2.67360.768
c 3.7960.89610
26d 12
‘‘Rate’’ dq
dCC
~{a2
dCC
dt
  
0.994860.0024
a 2.14560.442
a 4.3260.84610
26 0
Values are means 6 SD. Repeated Measures One-Way ANOVA: Goodness-of-fit values (r
2 and RMS error) - p,0.0001. Bonferroni’s Multiple Comparison Tests:
ap,0.001 vs. ‘‘uptake’’ model value,
bp,0.01 vs. ‘‘uptake’’ model value. Paired t-tests:
cp,0.02 vs. ‘‘constant’’ model value,
dp,0.002 compared to q1 values determined from linear fit of pre-injection pO2 data (t#0) {q1=4.3761.02610
26 [ml O2/(10
5 cells min)], mean 6 SD, n=20}.
doi:10.1371/journal.pone.0037471.t002
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37471could be predicted by Equation 25. The solid curve in the figure
shows the predicted relationship, assuming the same mean
parameter values used to fit the data. Given the fact that the
MKT-077 concentration at the end of the experiments may
underestimate CC,‘, the curve describes the data reasonably well.
Relationship between Transient MKT-077 Uptake and
MKT-077-Induced Metabolic Inhibition
The theoretical relationship between relative consumption
change and MKT-077 uptake can be generated by rearranging
Equation 3 and substituting the expression for e
kt into Equation
21:
qC C ðÞ ~q1z
ar k
2CC,?
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p
  
CC 2CC,?{CC ðÞ ½ 
%DqC C ðÞ ~{100
ar k
2q1
  
CC 2CC,?{CC ðÞ
CC,?
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CM0
p
   ðEq 26Þ
Plots of Equation 26 for the three different doses of MKT-077
are shown in Figure 6 using the mean parameter values generated
from the model fits. The steep initial rise in these curves indicates
that initial small amounts of drug uptake significantly decrease
oxygen consumption. Interestingly, for a given cellular uptake,
2 mg/ml MKT-077 impacts oxygen consumption to a greater
extent than 4 or 6 mg/ml, although it takes much longer to achieve
a given concentration at the lower doses.
MKT-077-Induced Metabolic Inhibition of Human Breast
Carcinoma Cells
To demonstrate that MKT-077 was also effective at inhibiting
oxygen consumption in human breast cancer cells, suspensions of
MDA-MB231 cells were exposed to 0 (n=2), 2 (n=4), 4 (n=3), or
6( n=2 )mg/ml MKT-077 in the metabolic chamber, and the pO2
was measured. The intracellular concentration of MKT-077 was
determined spectrophotometrically at the end of each experiment,
and this final concentration was assumed to be an estimate of the
steady-state value, CC,‘.
As predicted by Equation 2, the final MKT-077 concentration
was strongly positively correlated with the media MKT-077
concentration (r
2=0.908, n=9, data not shown). The slope of this
relationship, w, was 0.011 ml/(ng MKT-077). Thus, similar to the
R3230Ac cells, the MDA-MB231 cells took up MKT-077 in a
dose-dependent fashion. Equation 2 was used to calculate the CC,‘
values used in subsequent model fits.
The pO2 profiles were fitted to Equation 20. Since no transient
uptake data were available, the parameter k had to be determined,
along with P*, q1, and ar, using nonlinear least-squares regression
(GraphPad Prism). Examples of three pO2 curves for the MDA-
MB231 cells are shown in Figure 7A. When PBS was added to the
chamber at time zero, there was no noticeable change in the slope
of the pO2 curve. After the addition of 2 mg/ml MKT-077, the
slope began to grow shallower, indicating a decrease in
consumption. When 4 mg/ml MKT-077 was added, the change
in the pO2 curve was even more obvious, indicating a larger
decrease in consumption. It should be noted that the slope of the
4 mg/ml pO2 data is less than the other two slopes before addition
of MKT-077, i.e., at times less than zero. The basal consumption
rate, q1, for these cells was 2.85610
26 ml O2/(10
5 cells min),
compared to 3.70 and 4.12610
26 ml O2/(10
5 cells min) for the
cells treated with 0 and 2 mg/ml MKT-077, respectively. This fact
slightly exaggerates the pO2 change for the cells following addition
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37471of the 4 mg/ml dose, since the curves do not start at the same
ordinate at time zero. Regardless, the functional change and
qualitative effect is the same.
Equation 20 described the MKT-077-induced pO2 decreases
reasonably well (Figure 7A). The mean r
2 value for all of the fits
was 0.99660.008 (n=9). There were no differences among the
four fitted parameters for the three groups (p.0.12, Kruskal-
Wallis test). The mean value of k, the inverse of the time constant
for drug uptake, was 20.01360.007 min
21 (mean 6 SD, n=9).
The mean value of the proportionality constant, ar, was
5.7862.23610
24 [ml O2 (10
5 cells)
0.5]/(ng MKT-077)
0.5, and
the basal oxygen consumption rate, q1, was 3.1361.08610
26 [ml
O2/(10
5 cells min)].
As was the case for the R3230Ac cells, MKT-077 caused a
decrease in oxygen consumption rate in MDA-MB231 cells
(Figure 7B). The mean percent decreases in consumption were
57.268.7% (n=4), 72.769.5% (n=3), and 78.266.8% (n=2) for
the 2, 4, and 6 mg/ml doses, respectively. These values were
Figure 4. Modeled changes in pO2 and predicted oxygen consumption changes after treatment with MKT-077. A) Average pO2
measured in R3230Ac cell suspensions before and after addition of different concentrations of MKT-077 (0, 2, 4, or 6 mg/ml) to air-saturated medium
at t=0 minutes. Curves are the ‘‘relative rate’’ model equations (Equations 14 and 20) calculated using the mean fitted parameters (Table 3). B)
Predicted oxygen consumption, q, calculated using Equations 10 and 21 and the mean fitted parameters (Table 3).
doi:10.1371/journal.pone.0037471.g004
Figure 5. Relative change in oxygen consumption as a function of extracellular and intracellular MKT-077 concentration. A) Percent
decrease in oxygen consumption of R3230Ac cells, %Dq, as a function of [MKT-077] in medium. The points are staggered along the abscissa for
clarity, and the horizontal bars represent the mean values. The %Dq values were significantly dependent on dose (ANOVA, p=0.003). The dashed line
is a linear regression: %Dq=6.99CM0+32.2, r=0.706, p=0.0005, n=20. The solid curve is the predicted relationship calculated from Equation 24 using
the mean parameters. *p,0.01 compared to the 2 mg/ml group using one-way ANOVA with Bonferroni’s Multiple Comparison Test. B) Percent
decrease in oxygen consumption of R3230Ac cells, %Dq, as a function of steady-state MKT-077 uptake. The dashed line is a linear regression:
%Dq=0.664CC,‘+41.7, r=0.621, p=0.004, n=20. The solid curve is the predicted relationship calculated from Equation 25 using the mean
parameters. (&): 2 mg/ml MKT-077, n=7; (m): 4 mg/ml MKT-077, n=7; (N): 6 mg/ml MKT-077, n=6.
doi:10.1371/journal.pone.0037471.g005
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extracellular doses of MKT-077 resulted in more cellular drug
uptake, which tended to cause larger decreases in oxygen
consumption. The theoretical consumption decrease predicted
by Equation 25 is shown in Figure 7B and was calculated using the
median parameter values, since the number of experiments was
relatively small. The curve matched most of the data reasonably
well.
Discussion
Modeling of In Vitro Cellular MKT-077 Uptake
In this paper, we theoretically modeled the uptake of the
lipophilic cation, MKT-077, by R3230Ac rat mammary adeno-
carcinoma cells and linked the uptake to the driving forces
responsible for drug diffusion into the cells. The key parameters
are the extracellular MKT-077 concentration, the mass transfer
coefficient across the cell membrane (k), the plasma membrane
potential, and the mitochondrial membrane potential, which is
related to the model parameter b. We tested three extracellular
MKT-077 doses, which reflect the lower end of that used during
preclinical studies [12,13,15,16]. Not surprisingly, final steady-
state MKT-077 uptake was dose-dependent, such that a higher
extracellular concentration of MKT-077 resulted in a greater
steady-state uptake. Since the time constant describing the drug
uptake is the inverse of the parameter k (Equation 4) and k was
not statistically different among the groups, there was no difference
in the time to reach steady state (time constant ,30 minutes,
Figure 1B). Thus, the increased steady-state uptake was entirely
caused by the faster uptake rate initially (Figure 1C) and
throughout the course of the experiment at the higher drug doses,
rather than by an extended uptake time. Since the model
parameters associated with cellular transport did not change with
MKT-077 dose (Table 1), the difference in uptake rate and final
concentration could be entirely attributed to the extracellular
concentration differences. Therefore, our modeling showed that
the final achievable intracellular concentration was entirely
dependent on the extracellular drug concentration and that the
drug exposure had no impact on the inherent cellular transport
parameters.
Overall uptake of MKT-077 has also been characterized in CX-
1 colon carcinoma cells, which took up ,30 ng/10
5 cells after two
hours of treatment with 3 mg/ml MKT-077 [15]. R3230Ac cells
exhibited a similar average uptake after two hours when treated
with 4 mg/ml (30.2 ng/10
5 cells). Based on our modeling, we
Figure 6. Theoretical relative decrease in oxygen consumption
of R3230Ac cells as a function of MKT-077 uptake. R3230Ac cells
were treated with 2, 4, or 6 mg/ml MKT-077 at t=0 minutes. Percent
decrease in consumption, %Dq, was calculated from Equation 26 using
the mean fitted parameters (Table 3). Points indicate values after
30 minutes (N) or 2 hours (m) of MKT-077 exposure.
doi:10.1371/journal.pone.0037471.g006
Figure 7. Effect of MKT-077 on pO2 and oxygen consumption in MDA-MB-231 cells. A) Change in pO2 measured in MDA-MB231 cell
suspension before and after addition of different concentrations of MKT-077 (0, 2, or 4 mg/ml) to air-saturated medium at t=0 minutes. Points are
measured pO2 data. Curves are fits of data to the ‘‘relative rate’’ model (Equations 14 and 20). B) Percent decrease in oxygen consumption of MDA-
MB231 cells, %Dq, as a function of steady-state MKT-077 uptake. The solid curve is the predicted relationship calculated from Equation 25 using the
medians of the fitted parameters: q1=2.91610
26 ml O2/(10
5 cells min), ar=6.04610
24 ml O2 (10
5 cells)
0.5]/(ng MKT-077)
0.5, and k=20.101 min
21.
(&): 2 mg/ml MKT-077; (m): 4 mg/ml MKT-077; (N): 6 mg/ml MKT-077.
doi:10.1371/journal.pone.0037471.g007
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properties, e.g., similar mitochondrial transmembrane potentials.
These intracellular levels of MKT-077 are extremely high and are
indicative of the ability of these carcinoma cells to concentrate a
lipohilic compound like MKT-077. A concentration of 30 ng/10
5
cells is approximately 398 mM, compared to the extracellular
concentration of 4 mg/ml or 9.3 mM. Thus, the final intracellular
concentration is 40–50 times higher than that outside the cell
[Equation 2; ratio=(1+b)e
c].
Intracellular accumulation of MKT-077 is the result of several
different mechanisms. Extracellular MKT-077 enters cells due to
concentration and potential differences across the plasma mem-
brane. The MKT-077 that enters the cells either remains free in
the cytoplasm or is ‘‘bound’’ to cellular components. This
‘‘bound’’ drug could include drug linked to receptors or drug
concentrated within organelles, such as mitochondria. Based on
earlier studies that showed very large mitochondrial uptake of
MKT-077 [15,16], we assumed that ‘‘bound’’ drug (Cb) was
primarily attributable to drug sequestered in the mitochondria,
i.e., the drug bound to receptors was negligible. The concentration
of mitochondrial MKT-077 can be considered proportional to the
cytoplasmic concentration (Equation A2) [29]. The model based
on these assumptions fitted the data well and showed that the
‘‘bound’’ form accounted for the majority of the large increase in
total cellular MKT-077 concentration, while the cytoplasmic
concentration (Ci) contributed little (Figure 1A). The ability of the
model to adequately describe the data suggests that the
assumptions are reasonable. They are consistent with the idea
that the mitochondrial membrane potential is the major driving
force for the cellular drug accumulation [15,16].
Although the mitochondrial membrane potential is most likely
the major factor responsible for the large MKT-077 accumulation,
MKT-077 certainly binds to receptors within cells and this could
also influence the uptake. MKT-077 has been shown to bind to F-
actin [30], telomerase [31], and several members of the Hsp70
family, including mortalin (mot-2/mthsp70/GRP75) [32,33,34]
and HSC70 [30]. Recently, it has been proposed that binding of
MKT-077 to these molecules is the basis of its cytotoxic effects,
rather than the mitochondrial damage as proposed originally
[15,16,18]. The exact mechanism responsible for the cytotoxicity
is currently unknown, but several hypotheses have been proposed,
including general mitochondrial disruption and inhibition of
electron transport chain enzymes [15,16], competitive mot-2
binding that releases p53 [34], suppression of ras transformation
by blocking membrane ruffling [30], and inhibition of telomerase
activity [31]. The majority of these effects are independent of
MKT-077 mitochondrial accumulation and the resultant meta-
bolic inhibition. Thus, as suggested by Naasani et al., the cytotoxic
effects of MKT-077 may not be related to the mitochondrial
accumulation [31]. While binding of MKT-077 to receptors may
play a role in cytoxicity, there is significant evidence that it does
not significantly contribute to the large cellular accumulation of
the drug. First, confocal microscopy of human pancreatic
carcinoma cells exposed to MKT-077 showed that the cells took
up large amounts of the drug and that the uptake was almost
exclusively localized to the mitochondria [15]. Normal monkey
epithelial cells showed no detectable drug in the cytoplasm or
mitochondria [15], suggesting that binding to intracellular
receptors was below the detection level. Second, simple binding
estimates show that this mechanism would contribute little to the
overall drug uptake. For example, if we assume that binding
between MKT-077 and a receptor is complete and irreversible (an
unrealistic, but optimal situation), even a 5 mM receptor concen-
tration would result in a bound MKT-077 concentration of
0.38 ng/10
5 cells. This would represent only 1.1% of the total
MKT-077 in the cells when the extracellular MKT-077 concen-
tration is 4 mg/ml (CC,‘=33.8 ng/10
5 cells). Finally, our model
described the data well when we assumed that the receptor
binding was negligible. Most likely, the receptor binding charac-
teristics would have been nonlinear, rather than the simple
constant ratio we assumed for the mitochondrial uptake. Thus, a
significant contribution from such nonlinear components would be
expected to result in poor model fits. Thus, in agreement with
earlier studies [15,16,18], our data and model confirm that MKT-
077 accumulates to such a large extent in the mitochondria
because of the high mitochondrial membrane potential.
Another possible impact of the binding of MKT-077 to
receptors could be its possible role in mitochondrial accumulation.
Of the currently identified receptors, mot-2 is the only known
mitochondrial molecule that interacts with MKT-077. Mot-2 is
primarily located in the mitochondria [35], and it can bind to
MKT-077 at a single binding site within its p53-binding region
[34]. Thus, binding of drug to these molecules could theoretically
account for some of the MKT-077 present in the mitochondria.
While this could occur, we again would not expect it to
significantly contribute to the mitochondrial accumulation, based
on the concentration argument presented above. The mot-2
concentration within the mitochondria would have to be 23 mMt o
contribute 5% of the total MKT-077 concentration. Even if mot-
2-binding did significantly contribute to the mitochondrial drug
uptake, it would have little effect on the overall interpretation of
the results. Its major impact would be that our estimates of
mitochondrial membrane potential (DYmit) are too high, since its
calculation is based on the assumption that the ‘‘bound’’ drug
concentration (Cb) is completely attributable to drug taken up by
the mitochondria as a result of the transmembrane potential
(Equation 6). Therefore, it should be noted that the calculated
values of DYmit are estimates, although we believe that they are
close to the true values.
In our model, we assumed that the plasma membrane and
mitochondrial transmembrane potentials remained constant dur-
ing the MKT-077 exposure. Since the drug accumulates in the
mitochondria, it is possible that the mitochondrial transmembrane
potential could change as MKT-077 is bound. However, since the
model fitted the data well, we have no reason to doubt the validity
of this assumption. In addition, if MKT-077 had an impact on
mitochondrial membrane potential, we would have expected to
see a significant impact of MKT-077 dose on the fitted values of b
and thus mitochondrial transmembrane potential, DYmit. How-
ever, there was no difference in b or DYmit among the dose
groups. Finally, three experiments were performed to determine if
there was a change in mitochondrial transmembrane potential in
the presence of MKT-077. R3230Ac cells were exposed to 6 mg/
ml MKT-077 for 0–120 minutes, and mitochondrial potential was
assayed using a JC-1 mitochondrial membrane potential assay kit
(Cat. No. 10009172, Cayman Chemical Co., Ann Arbor, MI).
With this assay the ratio of red-to-green fluorescence is a measure
of the mitochondrial membrane potential [36]. MKT-077 had no
impact on the red-to-green ratio (data not shown), indicating that
the mitochondrial membrane potential was unaffected by MKT-
077.
The model described all aspects of the uptake reasonably well,
including the time course (Figure 1B) and the magnitude of the
final steady-state concentration, CC,‘ (Figure 1D). The model
tended to underestimate the initial uptake rate of MKT-077 when
cells were exposed to 6 mg/ml (Figure 1C). Since the initial uptake
rate is proportional to kc (Equation 5), this product may have been
affected by the higher dose of drug. The parameter c, which
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constant, but the fitted k value tended to be higher in the 6 mg/ml
group, but was not significantly different. It is possible that c or
DYpmem was slightly affected by this high level of MKT-077,
which resulted in a small decrease in viability after 90 minutes of
exposure. Thus, our assumptions may have resulted in a slight
underestimate of the initial uptake rate for the 6 mg/ml dose.
Nevertheless, the lack of any statistically significant differences in
the parameters shows that the doses of MKT-077 had very little
impact on the cellular parameters, including DYpmem and DYmit.
Modeling MKT-077-Induced Metabolic Inhibition as a
Function of Cellular Drug Uptake
In our experimental system to determine oxygen consumption,
it was observed that once the pO2 in the chamber dropped below
20 mm Hg, there were changes in cellular oxygen consumption,
even in saline-treated controls. This limited the length of time
during which reliable data could be obtained for some dose
groups. The source of this behavior was most likely the time course
of the pO2 changes in the system. In one study using rat
hepatocytes, when oxygen levels changed quickly (,40 minutes),
rates of oxygen consumption did not change until pO2 fell below
10 mm Hg [37]. However, when oxygen levels gradually fell over
several hours, changes in consumption were sometimes seen at
pO2 levels as high as 70 mm Hg. Since oxygen levels could
adequately be described as falling more gradually in our
experiments, decreases in oxygen consumption below 20 mm
Hg could be explained by this phenomenon.
Since cell viability remained above 90% throughout all of the
experiments, the changes in chamber pO2 were the result of
MKT-077-induced changes in oxygen consumption rate, rather
than a decrease in cell number. There was a small loss of viability
when cells were exposed to 6 mg/ml MKT-077 for 90 minutes or
more, but this would have had little effect on our results. Since the
time constant of the consumption decrease was 60 minutes [1/
(2k)], more than 63% of the consumption change had already
occurred before there was any significant cell loss. Thus, the large
decreases in oxygen consumption seen in these experiments
cannot be explained by loss of cell viability.
Modeling of the pO2 data provided detailed information on
cellular metabolic changes as a function of drug uptake. Although
we originally hypothesized that the consumption change would be
proportional to the amount of drug taken up by the mitochondria,
this assumption resulted in poor data fits (Figure 3 and Table 2).
Surprisingly, the data were best described by a model in which the
change in consumption with MKT-077 uptake was proportional
to the relative rate of drug uptake (Figures 2 and 3 and Table 2).
Based on this model, consumption decreased monoexponentially
with a time constant of 1/(2k)( ,60 minutes, Equation 21). Since
the parameter k is essentially the ratio of the driving force for
cytoplasmic MKT-077 uptake to the driving force for mitochon-
drial drug uptake (Equation 4), the magnitude of the time constant
would increase as the mitochondrial transmembrane potential (or
b) grows larger. Thus, assuming other parameters remain
unchanged, consumption should decrease more quickly in cells
with greater mitochondrial transmembrane potentials, i.e., more
negative potentials. Therefore, MKT-077 would be most effective
in cells with large mitochondrial membrane potentials. This result
also suggests that it might be useful to try to increase the absolute
mitochondrial membrane potential, i.e., make it more negative,
before exposing the cells to MKT-077. If this were possible, such a
combination could improve the efficacy of MKT-077 as a
potential radiosensitizer.
The change in oxygen consumption was a complex relationship
involving a quadratic function of MKT-077 uptake and extracel-
lular drug concentration (Equation 26). As evident in Figure 6,
cells that were treated with lower concentrations of MKT-077
required less drug accumulation to achieve the same level of
inhibition than cells treated with higher doses. For example, 2 mg/
ml MKT-077 reduced oxygen consumption by ,30% after the
accumulation of ,7 ng/10
5 cells, while cells treated with 6 mg/ml
MKT-077 required an uptake of ,11 ng/10
5 cells to achieve the
same result. It should be noted, however, that it took 30 minutes of
drug exposure at the 2 mg/ml dose to achieve this level of
inhibition, while at the higher dose, only about 10–12 minutes of
exposure was necessary. Thus, at any given time, higher
extracellular drug concentrations resulted in higher MKT-077
uptakes and larger decreases in oxygen consumption (Figures 4B
and 6). Nevertheless, this result means that low external MKT-077
concentrations can still be effective at significantly inhibiting
consumption, even though a smaller amount of drug accumulates
in the tumor. A potential benefit of this feature is that lower
external drug concentrations would also be expected to decrease
accumulation in normal tissues, and should reduce any normal
tissue toxicity. Therefore, in an in vivo study, it could be beneficial
to infuse MKT-077 at a slower infusion rate, even though it results
in a lower plasma drug concentration. This protocol should still
decrease tumor oxygen consumption, but may minimize any toxic
side effects.
In Vitro MKT-077-Induced Steady-State Metabolic
Inhibition
As might be expected, increasing the dose of MKT-077 yielded
an increase in final steady-state metabolic inhibition. Somewhat
surprisingly, the overall decrease in consumption was not directly
proportional to the steady-state intracellular MKT-077 concen-
tration (Figure 5). Instead, our modeling revealed that the change
in consumption was actually proportional to the square root of the
final, steady-state intracellular MKT-077 concentration (Equation
25). This means that in order to double the decrease in
consumption it would be necessary to quadruple the final drug
concentration. However, the benefit of this relationship lies in the
fact that it increases the impact of small drug accumulations on
oxygen consumption. This effect is evident when the slope of the
curve in Figure 5B is considered. The changes in consumption for
a given change in uptake are greatest at concentrations less than
about 20 ng/10
5 cells. It is also evident that steady-state
intracellular MKT-077 concentrations as low as 5 ng/10
5 cells
(50 fg/cell or ,66 mM) can result in a metabolic inhibition of
20%. Thus, MKT-077 is a powerful inhibitor of oxygen
consumption in vitro, even at low cellular concentrations.
Our current study is the first to determine MKT-077-induced
metabolic inhibition in whole cells. In an earlier study using
mitochondria isolated from rat liver and muscle, as well as
mitochondria isolated from cultured CV-1 epithelial cells, CX-1
colon carcinoma cells, and CRL1420 pancreatic carcinoma cells,
MKT-077 was shown to effectively inhibit mitochondrial respira-
tion in each cell line in a dose-dependent manner [16]. Notably,
mitochondria from CV-1 cells required almost four times the
MKT-077 dose to exhibit the same level of inhibition as found in
CX-1 cells, highlighting the drug’s cellular selectivity. While such
data are valuable in a mechanistic sense, the use of whole cells
offers more meaningful information, since mitochondria can be
influenced by other cellular processes and since cellular uptake is
governed by transport through the plasma membrane. By using a
mathematical model linking the change in oxygen consumption
with cellular uptake, we were able to demonstrate the complex,
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levels and the extent of metabolic inhibition.
Comparison of MKT-077 Effects in R3230Ac and MDA-
MB231 Cells
Although we did not perform a detailed uptake analysis for the
MDA-MB231 cells, data from the consumption experiments
yielded information on the nature of MKT-077 uptake by these
cells. For example, the parameter w, the slope of the line relating
CC,‘ to CM0 (Equation 2), was 0.00845 ml/10
5 cells for the
R3230Ac cells, while it was 0.011 ml/10
5 cells for the MDA-
MB231 cells. The higher value of w for the MDA-MB231 cells
indicates that they tended to take up more MKT-077 than the
R3230Ac cells at any given extracellular concentration, i.e., CC,‘
was larger. Based on Equation 2, this could be caused by a greater
mitochondrial transmembrane potential (b) or a greater plasma
membrane potential (c) in the MDA-MB231 cells. From the
consumption modeling, we determined a value of k for the MDA-
MB231 cells of 20.013 min
21, which was 24% lower than the
mean value for the R3230Ac cells (20.017 min
21). Since k is the
inverse of the time constant governing MKT-077 cellular uptake,
one might predict that the MDA-MB231 cells would take up the
drug more slowly, but the drug uptake rate is dependent on both k
and CC,‘ (Equation A14). Since CC,‘ is larger for the MDA-
MB231 cells, the uptake rate is actually greater for the MDA-
MB321 cells compared to the R3230Ac cells at all times after one
minute.
MKT-077 resulted in a decrease in oxygen consumption rate in
both cell lines. Two-way ANOVA analysis of the percent decrease
in consumption data after exposure to 2, 4, and 6 mg/ml MKT-
077 for the two cell lines showed a significant impact of MKT-077
dose (p=0.009). There was no significant effect of cell line
(p=0.065), although there was a tendency for the inhibition in the
MDA-MB231 cells to be greater (57 vs 45%, 73 vs 62% and 78 vs
73% at the three doses).
There was no difference between the proportionality constants,
ar, for the two cell lines (p=0.870), and both had a value of about
5.8–5.9610
24 [ml O2 (10
5 cells)
0.5]/(ng MKT-077)
0.5. Whether
this constant would have a similar value for other cell lines remains
to be seen. It is not known what factors might impact ar.
The MDA-MB231 results show that human carcinomas also
take up MKT-077, resulting in inhibition of oxygen consumption.
Most likely, MKT-077 would have similar effects on other
carcinoma cell lines and could perhaps be effective in other types
of tumor cells as well. Clearly, multiple factors impact the uptake,
uptake rate, and the magnitude of metabolic inhibition, and these
would be expected to vary across cell lines.
Conclusion - Implications for In Vivo Applications of MKT-
077
In summary, these findings could have significant implications
for in vivo applications of MKT-077 or other cationic metabolic
inhibitors. First, large amounts of drug do not have to be delivered
to achieve a meaningful reduction in oxygen consumption.
Second, it might be beneficial to infuse a lower concentration of
MKT-077 for an extended period of time, thereby maximizing the
consumption change for a given amount of drug uptake and
minimizing uptake by normal tissues. Such lower MKT-077
infusion rates might mitigate any deleterious side effects of the
drug. In conclusion, MKT-077 shows promise as a metabolic
inhibitor and could prove useful as a means to increase tumor pO2
levels, thereby increasing the efficacy of radiotherapy.
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